NCT02905578 2025-08-27
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
University of Iowa
Phase 2 Completed
Clinical Trials
13 trialsNCT04879368 2025-07-17
INTEGRATEIIb
Australasian Gastro-Intestinal Trials Group
Phase 3 Active not recruiting
NCT04543071 2025-06-19
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Columbia University
Phase 2 Recruiting
NCT03535727 2024-12-31
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT03415854 2023-12-15
NABPLAGEMD
HonorHealth Research Institute
Phase 2 Completed
NCT02993731 2023-11-15
CanStem111P
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT04299880 2023-11-08
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT04983407 2023-10-30
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
Aravive, Inc.
Phase 1/2 Terminated
NCT01964430 2023-06-28
apact
Celgene
Phase 3 Completed
NCT02077881 2020-05-28
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
NCT02151149 2018-09-24
ABOUND 70+
Celgene
Phase 4 Completed
NCT01677559 2018-01-11
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Washington University School of Medicine
Phase 1 Completed
NCT01161186 2012-10-11
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
University of California, San Francisco
Phase 1 Completed